Equities

China Wah Yan Healthcare Ltd

China Wah Yan Healthcare Ltd

Actions
  • Price (HKD)0.38
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 17 2017.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

China Wah Yan Healthcare Limited is a Hong Kong-based investment holding company principally engaged in medical and healthcare businesses. The Company operates through three segments. Health Management segment is engaged in health management-related businesses. Medical and Well-being segment is engaged in tumor diagnosis and treatment, eye caring businesses, pharmaceutical manufacture, medical laboratory testing and gynecology and obstetrics businesses in China. Asset Management segment is engaged in the investment in financial assets, fixed assets and distressed assets, as well as loan financing.

  • Revenue in HKD (TTM)193.87m
  • Net income in HKD-133.72m
  • Incorporated1989
  • Employees120.00
  • Location
    China Wah Yan Healthcare Ltd36th Floor, Times Tower391-407 Jaffe RoadWanchai Hong KongHKG
  • Phone+852 21873085
  • Fax+852 21873570
  • Websitehttp://www.chinawahyan.com
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.